Italia markets open in 1 hour 26 minutes

Sanofi (SAN.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a portafoglio
84,60-0,76 (-0,89%)
Alla chiusura: 05:35PM CET
Schermo intero
Chiusura precedente85,36
Aperto85,76
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno84,49 - 86,38
Intervallo di 52 settimane74,92 - 91,14
Volume1.853.669
Media Volume1.897.779
Capitalizzazione106,196B
Beta (5 anni mensile)0,46
Rapporto PE (ttm)17,26
EPS (ttm)4,90
Prossima data utili04 feb 2022
Rendimento e dividendo (forward)3,20 (3,79%)
Data ex dividendo05 mag 2021
Stima target 1A103,64
  • GlobeNewswire

    New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma

    New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthmaPublished results reinforce well-established safety profile of DupixentPositive data formed the basis for FDA approval of Dupixent in these patients with certain types of moderate-to-severe asthm

  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares - October 2021

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,526,866,030 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n

  • GlobeNewswire

    Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates

    Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates Sanofi confirms Vaccines mid-term guidance of mid-to-high single-digit sales growth1, ambition to more than double Vaccines sales by the end of the decade2Broad pipeline of innovative vaccines, with a total of 10 candidates planned to advance into the clinic by 2025, six of which will leverage the recently established mRNA Center of ExcellenceHybrid Vaccines Inve